Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3349181
Max Phase: Preclinical
Molecular Formula: C23H38N2O2
Molecular Weight: 374.57
Molecule Type: Small molecule
Associated Items:
ID: ALA3349181
Max Phase: Preclinical
Molecular Formula: C23H38N2O2
Molecular Weight: 374.57
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCN(CC)C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4NC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Standard InChI: InChI=1S/C23H38N2O2/c1-5-25(6-2)21(27)18-9-8-16-15-7-10-19-23(4,14-12-20(26)24-19)17(15)11-13-22(16,18)3/h15-19H,5-14H2,1-4H3,(H,24,26)/t15-,16-,17-,18+,19-,22-,23+/m0/s1
Standard InChI Key: HVYKDVIWDWBQOJ-LHCIGQOGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 374.57 | Molecular Weight (Monoisotopic): 374.2933 | AlogP: 3.99 | #Rotatable Bonds: 3 |
Polar Surface Area: 49.41 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 0.50 | CX LogP: 2.96 | CX LogD: 2.96 |
Aromatic Rings: 0 | Heavy Atoms: 27 | QED Weighted: 0.81 | Np Likeness Score: 0.92 |
1. Rasmusson GH, Reynolds GF, Utne T, Jobson RB, Primka RL, Berman C, Brooks JR.. (1984) Azasteroids as inhibitors of rat prostatic 5 alpha-reductase., 27 (12): [PMID:6502599] [10.1021/jm00378a028] |
2. Rasmusson GH, Reynolds GF, Steinberg NG, Walton E, Patel GF, Liang T, Cascieri MA, Cheung AH, Brooks JR, Berman C.. (1986) Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding., 29 (11): [PMID:3783591] [10.1021/jm00161a028] |
3. Rasmusson GH, Reynolds GF, Steinberg NG, Walton E, Patel GF, Liang T, Cascieri MA, Cheung AH, Brooks JR, Berman C.. (1986) Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding., 29 (11): [PMID:3783591] [10.1021/jm00161a028] |
4. Ahmed S, Denison S.. (1998) Structure activity relationship study of known inhibitors of the enzyme 5 alpha-reductase (5AR)., 8 (5): [PMID:9871588] [10.1016/s0960-894x(98)00044-4] |
Source(1):